Medicare Opens $50 GLP-1 Access.
The program provides qualifying Medicare drug plan members access to select GLP-1 medications with a $50 monthly copay. It operates outside the regular Part D benefit payment system, meaning the copay does not count toward a deductible or out-of-pocket spending limits. Covered drugs include Foundayo tablets, Wegovy injections or tablets, and Zepbound KwikPen. Medicare’s covered GLP-1 drug list does not include single-dose Zepbound vials or pens.
Eligibility is not automatic. Beneficiaries must have Medicare drug coverage and meet BMI requirements. Those with a BMI of 35 or higher may qualify. Some patients with lower BMI levels may qualify if they also have conditions such as prediabetes, uncontrolled high blood pressure, chronic kidney disease, a previous heart attack or stroke, peripheral artery disease, or diastolic heart failure.
Oz Ties Obesity to Chronic Disease
Oz said GLP-1 drugs can help some patients who have struggled to lose weight, especially when obesity is connected to other health problems. He described the medications as useful when prescribed properly, but not as a replacement for diet, exercise, sleep, stress management, or other basic health habits.
“I’m a fan of GLP-1 drugs when used correctly,” Oz said in the interview. “They do help people who are overweight lose weight quite effectively.” He framed the medications as a possible starting point for patients whose weight limits mobility or worsens conditions such as high blood pressure and diabetes. Joint pain, reduced movement, and metabolic problems can make weight loss harder. Oz said the drugs may help some patients get enough momentum to pursue healthier routines.
Chronic Illness Drives U.S. Health Costs
The health-cost case behind the policy is large. Chronic diseases account for most illness, disability, and death in the United States. The latest federal chronic disease spending data shows 90% of the nation’s $5.3 trillion in annual health care expenditures are for people with chronic and mental health conditions.
Diabetes, heart disease, stroke, kidney disease, and obesity all carry high costs. More than 40 million Americans have diabetes. More than 115 million adults have prediabetes. Obesity affects about 40% of adults and is linked to a higher risk of type 2 diabetes, heart disease, and some cancers.
GLP-1 Drugs Move Beyond Weight Loss
GLP-1 drugs work by affecting appetite, fullness, digestion, and blood sugar regulation. Some patients eat less because they feel full sooner. Others may see improvements in weight-related metabolic markers.
Wegovy has also gained a broader role in heart-risk treatment. Federal regulators approved it in 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. That heart-risk-reduction approval helped strengthen the medical argument for GLP-1 coverage beyond weight loss alone.
Program Requires Doctor Approval
Patients cannot simply request the $50 GLP-1 benefit at a pharmacy and receive it immediately. A health care provider must prescribe the covered drug. The provider must also complete prior authorization when required. Medicare requires providers to certify that the patient is using the drug as part of a program focused on diet and exercise. That condition reflects a broader medical consensus: GLP-1 drugs work best when paired with long-term monitoring and behavior support.
Medicare Test Could Shape Future Coverage
The Bridge is temporary, but its results could affect future Medicare policy. The program gives federal officials a chance to track access, use, costs, and health outcomes before deciding what broader coverage should look like. For beneficiaries, the immediate change is simple: some people who could not afford GLP-1 weight-loss drugs may now have a lower-cost route. For Medicare, the larger test is whether that access improves health enough to justify the spending.
The program is scheduled to continue through Dec. 31, 2027. Until then, patients who think they may qualify must go through their doctor, meet eligibility rules, and receive authorization before using the new $50 monthly benefit.
